Author: PharmaSignal News Desk

AstraZeneca Virginia investment enhances ADC production capabilities with a $500 million boost.

AmgenNow platform enhances direct-to-consumer access, aiming to streamline patient engagement and improve market reach.

Novo Nordisk acquires Akero Therapeutics for $5.2 billion, enhancing its MASH treatment pipeline.

Colorado Enbrel payment limit set at $600 per unit, impacting Amgen’s pricing strategy and potentially influencing other states.

Domestic Generic Drug Fast-Track Review Program aims to expedite approval for drugs made from domestic materials.

Amgen Repatha pricing sees a 60% reduction in the U.S. through a new program, enhancing market access.

Generic mifepristone approval by FDA expands access to abortion care, offering a new option for patients.

EU pharmaceutical policy overhaul aims to improve access to medicines, impacting millions across Europe.

Chiesi Arbor partnership focuses on advancing gene editing therapies for rare diseases, targeting primary hyperoxaluria type 1.

Pharma companies are seeking agreements with Trump following Pfizer’s deal, aiming to lower drug prices.